Product news

Share this article:

GlaxoSmithKline announced that the European Commission has granted a marketing authorization for its cervical cancer vaccine, Cervarix, for all 27 European member states.  Cervarix is indicated for the prevention of precancerous cervical lesions and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. The indication is based on data generated in girls and women aged between 10 and 25.


Novo Nordisk announced that its Norditropin (somatropin [rDNA origin] injection) received approval from the FDA for the treatment of children with short stature associated with Turner syndrome.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions